Decatur Capital Management, Inc. Biomarin Pharmaceutical Inc Transaction History

Decatur Capital Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 23, 2019	SELL	$84.2 - $98.62 $7.11 Million - $8.32 Million	-84,400 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$80.14 - $106.07 $1.27 Million - $1.68 Million	15,800 Added 23.03%	84,400 $7.19 Million
Q3 2018 Nov 02, 2018	SELL	$93.92 - $105.72 $1.6 Million - $1.8 Million	-17,050 Reduced 19.91%	68,600 $6.65 Million
Q2 2018 Aug 01, 2018	BUY	$76.01 - $99.03 $6.51 Million - $8.48 Million	85,650 New	85,650 $8.07 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Decatur Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Decatur Capital Management, Inc. with notifications on news.